These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 29225265

  • 1. Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma.
    Osawa Y, Gozawa R, Koyama K, Nakayama T, Sagoh T, Sunaga H.
    Intern Med; 2018 Apr 01; 57(7):1015-1019. PubMed ID: 29225265
    [Abstract] [Full Text] [Related]

  • 2. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM, Ryder MM, Hilger CR, Bible KC.
    Thyroid; 2017 Jul 01; 27(7):923-927. PubMed ID: 28471306
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy and Safety of Lenvatinib for Unresectable Anaplastic Thyroid Cancer].
    Yamazaki H, Shimizu S, Iwasaki H, Yoshida T, Suganuma N, Yamanaka T, Kojima I, Masudo K, Toda S, Nakayama H, Masuda M.
    Gan To Kagaku Ryoho; 2017 Aug 01; 44(8):695-697. PubMed ID: 28860443
    [Abstract] [Full Text] [Related]

  • 4. Anaplastic Thyroid Carcinoma Treated with Lenvatinib.
    Ohkubo JI, Takahashi A, Ikezaki S, Takenaga F, Ohkubo Y, Suzuki H.
    Kurume Med J; 2018 Feb 26; 64(1.2):29-33. PubMed ID: 29057760
    [Abstract] [Full Text] [Related]

  • 5. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, Fukuda N, Sasaki T, Suzuki T, Ikezawa H, Dutcus CE, Tahara M.
    Future Oncol; 2019 Mar 26; 15(7):717-726. PubMed ID: 30638399
    [Abstract] [Full Text] [Related]

  • 6. Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer-A case report.
    Abhishek M, Renuka A, Ujjwal A, Amit C, Vijay P, Vanita N, Nandini M, Kumar P.
    Cancer Rep (Hoboken); 2022 Sep 26; 5(9):e1605. PubMed ID: 35243821
    [Abstract] [Full Text] [Related]

  • 7. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, Rassner M, Boerries M, Zielke A, la Rosee P, Meyer PT, Kroiss M, Weißenberger C, Schumacher T, Metzger P, Weiss H, Smaxwil C, Laubner K, Duyster J, von Bubnoff N, Miething C, Thomusch O.
    Thyroid; 2021 Jul 26; 31(7):1076-1085. PubMed ID: 33509020
    [Abstract] [Full Text] [Related]

  • 8. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
    Takahashi S, Tahara M, Ito K, Tori M, Kiyota N, Yoshida K, Sakata Y, Yoshida A.
    Adv Ther; 2020 Sep 26; 37(9):3850-3862. PubMed ID: 32676927
    [Abstract] [Full Text] [Related]

  • 9. A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib.
    Hamamoto T, Kono T, Taruya T, Ishino T, Ueda T, Takeno S.
    Auris Nasus Larynx; 2022 Jun 26; 49(3):515-519. PubMed ID: 33109426
    [Abstract] [Full Text] [Related]

  • 10. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.
    Kim SY, Kim SM, Kim JW, Lee IJ, Jeon TJ, Chang H, Kim BW, Lee YS, Chang HS, Park CS.
    Front Endocrinol (Lausanne); 2020 Jun 26; 11():599. PubMed ID: 32982983
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells.
    Kawamura Y, Saijo K, Imai H, Ishioka C.
    Cancer Sci; 2021 Nov 26; 112(11):4711-4721. PubMed ID: 34328666
    [Abstract] [Full Text] [Related]

  • 12. Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer.
    Date E, Okamoto K, Fumita S, Kaneda H.
    Invest New Drugs; 2018 Apr 26; 36(2):350-353. PubMed ID: 29018997
    [Abstract] [Full Text] [Related]

  • 13. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y, Onoda N, Ito KI, Sugitani I, Takahashi S, Yamaguchi I, Kabu K, Tsukada K.
    Thyroid; 2017 Sep 26; 27(9):1142-1148. PubMed ID: 28635560
    [Abstract] [Full Text] [Related]

  • 14. Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer.
    Yamazaki H, Yokose T, Hayashi H, Iwasaki H, Osanai S, Suganuma N, Nakayama H, Masudo K, Rino Y, Masuda M.
    Cancer Chemother Pharmacol; 2018 Oct 26; 82(4):649-654. PubMed ID: 30051190
    [Abstract] [Full Text] [Related]

  • 15. Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study.
    Yamazaki H, Yokose T, Hayashi H, Iwasaki H, Osanai S, Suganuma N, Nakayama H, Masudo K, Rino Y, Masuda M.
    Eur J Clin Pharmacol; 2020 May 26; 76(5):703-709. PubMed ID: 32034430
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis.
    Huang D, Zhang J, Zheng X, Gao M.
    Front Endocrinol (Lausanne); 2022 May 26; 13():920857. PubMed ID: 35846304
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE).
    Higashiyama T, Sugino K, Hara H, Ito KI, Nakashima N, Onoda N, Tori M, Katoh H, Kiyota N, Ota I, Suganuma N, Hibi Y, Nemoto T, Takahashi S, Yane K, Ioji T, Kojima S, Kaneda H, Sugitani I, Tahara M.
    Eur J Cancer; 2022 Sep 26; 173():210-218. PubMed ID: 35932627
    [Abstract] [Full Text] [Related]

  • 18. Drug safety evaluation of lenvatinib for thyroid cancer.
    Krajewska J, Kukulska A, Jarzab B.
    Expert Opin Drug Saf; 2015 Sep 26; 14(12):1935-43. PubMed ID: 26484847
    [Abstract] [Full Text] [Related]

  • 19. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME, Habra MA.
    Cancer Treat Rev; 2016 Jan 26; 42():47-55. PubMed ID: 26678514
    [Abstract] [Full Text] [Related]

  • 20. Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report.
    Tori M, Shimo T.
    BMC Cancer; 2018 Jun 28; 18(1):698. PubMed ID: 29954369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.